La experiencia de la medicina francesa en el acceso temprano a los nuevos tratamientos de boceprevir y telaprevir en combinación con el tratamiento tradicional de la hepatitis C de interferon y ribavirina ha mostrado sus resultados en pacientes cirróticos tratados en el 63 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) celebrado el mes pasado en Boston.
El estudio Cupic (ANRS CO20), se ejecuta bajo los auspicios de la Agencia Nacional para la Investigación sobre el SIDA y la hepatitis viral, es un estudio multicéntrico observacional en el entorno ATU de uso compasivo de los inhibidores de la proteasa del VHC en personas con cirrosis que fueron no respondedores a terapia previa basada en interferón y ribavirina.
Los resultados mostrados para estos pacientes, sin ser los que nos gustaría, si que mejoran en mucho sus opciones de cura y muestran que bien manejados pueden llevar el tratamiento hasta el final.
La noticia, en inglés, la publicamos a continuación por su interés:
Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported at The Liver Meeting 2012, the 63rdAnnual Meeting of the American Association for the Study of Liver Diseases (AASLD) last month in Boston.
Over years or decades people with chronic hepatitis C can develop serious liver disease, including cirrhosis or hepatocellular carcinoma. Whilst people with advanced liver damage are most urgently in need of treatment, they do not respond as well to interferon-based therapy, the current standard treatment for hepatitis C.
Pivotal trials of new drugs typically do not include the most difficult-to-treat patient groups, both because pharmaceutical companies want their candidates to perform as well as possible and because people with advanced disease are most likely to experience safety problems.
Such individuals may be able to access new treatments through early- and expanded-access programmes that run alongside controlled clinical trials, however. In France early access is available through the Temporary Authorisation for Use, or ATU, programme as drugs are awaiting marketing authorisation.
CUPIC (ANRS CO20), run under the auspices of the National Agency for Research on AIDS and Viral Hepatitis, is a multicentre observational study in the ATU setting of compassionate use of HCV protease inhibitors for people with cirrhosis who were non-responders to prior interferon-based therapy.
Christophe Hézode from Hôpital Henri Mondor in Paris presented findings from a 16-week analysis of nearly 500 CUPIC participants who were treated with boceprevir or telaprevir plus pegylated interferon and ribavirin.
The phase 3 SPRINT-2 and RESPOND-2 trials showed that people receiving triple therapy with boceprevir had more anaemia and dysgeusia (odd taste sensations) than those on pegylated interferon/ribavirin alone. The ADVANCE, ILLUMINATE, and REALIZE trials likewise showed that telaprevir recipients were more likely to experience anaemia, rash and pruritus (itching). However, Hézode noted, these studies included only a small number of people with liver cirrhosis – 115 total in the boceprevir trials and 247 in the telaprevir trials.
Between February 2011 and April 2012 a total of 674 treatment-experienced hepatitis C patients with cirrhosis were enrolled in the CUPIC cohort at 56 sites throughout France. The present analysis included 497 participants:
- 205 participants who received 800mg boceprevir every eight hours plus pegylated interferon alfa-2b (PegIntron) and 800-1400mg/day weight-adjusted ribavirin for 48 weeks, with a four-week interferon/ribavirin lead-in before starting boceprevir.
- 292 received 750mg telaprevir every eight hours plus pegylated interferon alfa-2a (Pegasys) and 1000-1200mg/day weight-adjusted ribavirin for 12 weeks, followed by interferon/ribavirin alone through week 48.
A majority of participants (68%) were men and the average age was 57 years. About half had HCV subtype 1b, 30 to 40% had harder-to-treat subtype 1a and the rest had other genotypes. About two-thirds had high baseline HCV viral load (>800,000 IU/mL). At baseline they had normal haemoglobin levels and platelet counts. Participants had compensated cirrhosis; most had Child-Pugh class A liver function (the least severe level) and MELD scores below 10.
Although only 2% of boceprevir recipients experienced rapid virological response at week 4, 38% went on to do so by week 8, 55% at week 12 and 58% at week 16 in an intent-to-treat analysis. In a per-protocol or as-treated analysis, the corresponding rates were 3, 42, 64 and 77%, respectively.
Telaprevir proved more effective overall. The rapid response rate at week 4 was 55%, rising to 80% by week 8 and 79% at week 12, but falling back to 67% at week 16 in an intent-to-treat analysis. In the per-protocol analysis response rates remained high at 58, 92, 93 and 92%, respectively.
Among boceprevir recipients, 33% experienced serious adverse events, 26% stopped treatment early and 7% did so due to adverse events. One patient died, six experienced hepatic decompensation, and five had serious (grade 3/4) infections. None developed severe rash or kidney failure.
Looking at haematological side-effects, 23% developed grade 2 anaemia (haemoglobin 8.0-9.0 g/dL), 4% developed grade 3/4 anaemia (<8.0 g/dL), 46% used erythropoietin, 6% received blood transfusions and 11% had ribavirin dose reductions. In addition, 1% developed grade 3 and 3% developed grade 4 thrombocytopenia (low platelet count), whilst 5% developed grade 3 and 2% developed grade 4 neutropenia (low white blood cell count).
Telaprevir was less well tolerated overall. Amongst telaprevir recipients 45% experienced serious adverse events, 23% stopped treatment early and 15% did so for this reason. Five patients died, six experienced hepatic decompensation, 19 had serious infections, 14 (5%) developed severe rash and five experienced kidney failure.
Turning to haematological events, 19% developed grade 2 anaemia, 12% developed grade 3/4 anaemia, 54% used erythropoietin, 16% received transfusions and 13% had ribavirin dose reductions. About 10% developed grade 3 and 3% developed grade 4 thrombocytopenia, but only 2% developed grade 3 and fewer than 1% developed grade 4 neutropenia.
In a multivariate analysis, low platelet level (<100,000/mm3) and low serum albumin (<35 g/L) at baseline were significant predictors of severe complications, including death, severe infection, or decompensation (odds ratios of 3.1 and 6.3, respectively). Female sex, being age 65 or older, and low haemoglobin at baseline predicted severe anaemia or need for blood transfusion.
“In this large cohort of compensated cirrhotic patients, the safety profile of telaprevir or boceprevir in triple combination was poor as compared with phase 3 trials” – with increased rates of serious adverse events and more difficult management of anaemia – “but associated with high rates of on-treatment virologic response”, the CUPIC researchers concluded.
The risk/benefit ratio should be assessed for treatment-experienced cirrhotic individuals with low platelet or serum albumin levels and “these patients should be treated on a case-by-case basis due to high risk to develop severe complications”, they added. Cirrhotic treatment-experienced patients without predictors of severe complications “should be treated but cautiously and carefully monitored”.
Hézode C et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 497 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. 63rd Annual Meeting of the American Association for the Study of Liver Disease, Boston, abstract 51, 2012. View the abstract on the conference website.